- Home
- RM vs SLN Comparison
RM vs SLN Comparison
Compare RM & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RM
- SLN
- Stock Information
- Founded
- RM 1987
- SLN 1994
- Country
- RM United States
- SLN United Kingdom
- Employees
- RM N/A
- SLN N/A
- Industry
- RM Finance: Consumer Services
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- RM Finance
- SLN Health Care
- Exchange
- RM Nasdaq
- SLN Nasdaq
- Market Cap
- RM 414.8M
- SLN 299.4M
- IPO Year
- RM 2012
- SLN N/A
- Fundamental
- Price
- RM $43.75
- SLN $4.81
- Analyst Decision
- RM Hold
- SLN Buy
- Analyst Count
- RM 2
- SLN 5
- Target Price
- RM $30.00
- SLN $32.60
- AVG Volume (30 Days)
- RM 52.0K
- SLN 61.8K
- Earning Date
- RM 07-30-2025
- SLN 08-07-2025
- Dividend Yield
- RM 2.74%
- SLN N/A
- EPS Growth
- RM 35.30
- SLN N/A
- EPS
- RM 3.47
- SLN N/A
- Revenue
- RM $591,436,000.00
- SLN $27,169,000.00
- Revenue This Year
- RM $16.20
- SLN N/A
- Revenue Next Year
- RM $7.43
- SLN N/A
- P/E Ratio
- RM $12.63
- SLN N/A
- Revenue Growth
- RM 7.19
- SLN 22.28
- 52 Week Low
- RM $25.41
- SLN $1.97
- 52 Week High
- RM $43.91
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- RM 82.31
- SLN 34.88
- Support Level
- RM $36.88
- SLN $4.91
- Resistance Level
- RM $42.05
- SLN $5.34
- Average True Range (ATR)
- RM 1.29
- SLN 0.48
- MACD
- RM 0.49
- SLN -0.05
- Stochastic Oscillator
- RM 98.79
- SLN 0.71
About RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.